Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 145 Publications

22 Customer Reviews

  • Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  •  

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

    Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NYP1eplvS3m2b4TvfIlkKEG|c3H5 M1TlV|UxKM7:TR?= NIH2TmQ1QCCq NIqyfG9FVVOR NXnpdIhRU2mubIOgZ4VtdHNiYomgcY9z\SC2aHHuJFk6LQ>? NXL5R2tkOTB2OUm2OFM>
OVCA 429 M{TsfGZ2dmO2aX;uJGF{e2G7 MnvoN|AxKG6P MUi0PEBp MoLrSG1UVw>? MV3EbZNzfXC2czDpcpRi[3RibYXseIlk\WyudXzhdkB1fW2xcjDzdIhmem:rZIO= MkW2NVA6QTl5Nk[=
RPMI8226 NFv6OGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7md5ZxOTByIH7N NWDtcIRxPDhiaB?= MorCSG1UVw>? Mmj3TWM2OD1|MDDuUS=> NVy0[|MzOTF|ME[0PFk>
Dox40 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPFN2dHOTByIH7N MnnpOFghcA>? MXfEUXNQ MnnJTWM2OD12MDDuUS=> MU[xNVMxPjR6OR?=
MR20 NUfBeItST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWxNFAhdk1? M4PrTlQ5KGh? M2XkR2ROW09? MoO3TWM2OD1{MDDuUS=> M3PFV|EyOzB4NEi5
LR5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLMNVAxKG6P NF;XWGM1QCCq M2LmcWROW09? MmDhTWM2OD1{MDDuUS=> M2T0SFEyOzB4NEi5
U266 NEOybJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnqNIUyODBibl2= NHLIXJo1QCCq M1HqOGROW09? MlvOTWM2OD1|IH7N NX7VXJA4OTF|ME[0PFk>
IM-9 MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6xNFAhdk1? M1j2NVQ5KGh? NWrzPWljTE2VTx?= NWDNTJFCUUN3ME22JI5O NVTy[HZMOTF|ME[0PFk>
Hs Sultan MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWwRWJmOTByIH7N MkPCOFghcA>? M3nPSGROW09? M2GyfGlEPTB;MkCgcm0> MofRNVE{ODZ2OEm=
PAM-LY2 NH76OXNHfW6ldHnvckBCe3OjeR?= NFjrVnkyODBibl2= M{L6RVEzKGh? MnzCSG1UVw>? MkLkTY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= MXyxNVM2ODlzMx?=
PAM 212 MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DtVlExOCCwTR?= MXK3NkBp M3Hh[GROW09? MoLvTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MUixNVM2ODlzMx?=
PAM-LY2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\oVFExOCCwTR?= MX63NkBp NGm4d2pFVVOR MX3Jcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NXK5RmtJOTF|NUC5NVM>
B4B8 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKxNFAhdk1? MYW3NkBp NHz1THhFVVOR NI\mZZlKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M3GyUlEyOzVyOUGz
B7E3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSxNFAhdk1? NHToPHE4OiCq MWHEUXNQ MXzJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MU[xNVM2ODlzMx?=
UM-SCC-9 M2TZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXJWVYyODBibl2= MorVO|IhcA>? MlraSG1UVw>? NHnkNJhKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NGHX[5QyOTN3MEmxNy=>
UM-SCC-11B M{LrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17kW|ExOCCwTR?= M1PldFczKGh? MnLOSG1UVw>? MYXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MVexNVM2ODlzMx?=
H460 MmPNSpVv[3Srb36gRZN{[Xl? NUnj[IpSOTBizszN NYHnS3RQOjRiaB?= NGPFSYxFVVOR MXXJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 Mn\1NVI1QTJzMUe=
U266 NXLOZmM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPK[|JDPTByIH7nM41t MV20PEBp MWDEUXNQ MX;Jcohq[mm2czDj[YxtKGe{b4f0bC=> MlHQNVI3OzF4MUm=
ARH77 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLqOVAxKG6pL33s M3XEWFQ5KGh? MkP1SG1UVw>? NEXmOIhKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NFX0V4IyOjZ|MU[xPS=>
WAD-1 M1\ySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy1NFAhdmdxbXy= MlewOFghcA>? NFfSUXBFVVOR Mo\VTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NFvR[WQyOjZ|MU[xPS=>
U266/LR7 NI\iWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\mVWc2ODBibnevcYw> NGLMV|I1QCCq M2LlT2ROW09? Mmq5TY5pcWKrdIOgZ4VtdCCpcn;3eIg> MkXHNVI3OzF4MUm=
U266/dox4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILQN5Y2ODBibnevcYw> NYfreWdnPDhiaB?= NEK4XpFFVVOR MnjoTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MYmxNlY{OTZzOR?=
RPMI8226/LR5 M2[zS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq1NFAhdmdxbXy= M1Oxc|Q5KGh? MmrHSG1UVw>? MXnJcohq[mm2czDj[YxtKGe{b4f0bC=> MXmxNlY{OTZzOR?=
H460 NGjPVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjGZVkyOCEQvF2= M3foVFczKGh? MX;EUXNQ NWLNNlNpUUN3ME2xNFAhdk1? NHK1SoQyOjZ|MU[yNC=>
H358 NGLWcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2xNEDPxE1? MkXLO|IhcA>? MWrEUXNQ M{HXNGlEPTB;N{Cgcm0> NIe0[I8yOjZ|MU[yNC=>
H322 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjjNVAh|ryP M4PqTFczKGh? MYTEUXNQ M3yzPGlEPTB;NkKwJI5O Ml7CNVI3OzF4MkC=
H460 MWrGeY5kfGmxbjDBd5NigQ>? M4Xo[|ExOCCwTR?= M3LGN|I1KGh? NIjwVJRFVVOR Mmf1TY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? NF\IcJYyOjZ|MU[yNC=>
LNCap-Pro5 NVO0RoRsTnWwY4Tpc44hSXO|YYm= NGjMOngyKM7:TR?= NVjHOmlEPCCq NFjCOo1FVVOR NIK4N2VUfGGkaXzpfoV{KHB3Mx?= NWHTOoFyOTR4MUK1N|I>
T29 NYjWcZJ6SXCxcITvd4l{KEG|c3H5 MVK1NEBvVQ>? NF\QfJY1QCCqIB?= MXHEUXNQ MXfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NW\3dINVOTZ5N{ixO|k>
T29Kt1 MlW1RZBweHSxc3nzJGF{e2G7 MWi1NEBvVQ>? MUK0PEBpKA>? M2H4SmROW09? M1\Ffmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Ml21NVY4PzhzN{m=
HCT116 NXnMTZpLSXCxcITvd4l{KEG|c3H5 MmO3OVAhdk1? MmT2OFghcCB? MX\EUXNQ MnGyTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M{Xm[|E3Pzd6MUe5
HKe-3 MXfBdI9xfG:|aYOgRZN{[Xl? MYO1NEBvVQ>? MlXMOFghcCB? NFn5SY5FVVOR NEfQc3BKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NFztTmcyPjd5OEG3PS=>
NB-1691 NEPZeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvi[5EyKM7:TR?= MlLqO|IhcA>? Mn\4TY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDVn NFntPHoyPzZ6OU[4OC=>
CHLA-255 NY\nRY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PvS|Eh|ryP MX[3NkBp NXXVOVBRUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKl M4m0SVE4Pjh7Nki0
SK-N-AS MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrERVYyKM7:TR?= NYrkfpRJPzJiaB?= M3\2cGlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW= NHS1UmgyPzZ6OU[4OC=>
NB-1691 MoLzSpVv[3Srb36gRZN{[Xl? MUexNEBvVQ>? MofoNlQhcA>? M{PPPHNq\26rZnnjZY51dHlicnXkeYNmeyClZXzsd{BqdiC2aHWgS|AwTzFicHjhd4U> NXvDSlRCOTd4OEm2PFQ>
CHLA-255 NFX2eJlHfW6ldHnvckBCe3OjeR?= MofsNVAhdk1? NFHWRWkzPCCq M2ruZ21w\GW|dHz5JJJm\HWlZYOgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOn M2PKVVE4Pjh7Nki0
RPMI 8226 NFTKZXFHfW6ldHnvckBCe3OjeR?= NFTxcmIzOCCwTR?= MmPqPEBp NF7LZoNUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NF:0SGUyQTR|NkC1NC=>
MM.1S NILNbVNHfW6ldHnvckBCe3OjeR?= MYCyNEBvVQ>? NYf5VmlVQCCq M{nWSXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MV:xPVQ{PjB3MB?=
U266 MkPhSpVv[3Srb36gRZN{[Xl? MX:yNEBvVQ>? NWPxTVh7QCCq NVqxflQ{W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MlfWNVk1OzZyNUC=
OPM1 MWfGeY5kfGmxbjDBd5NigQ>? NXfqR411OjBibl2= MYG4JIg> MWPTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MkDHNVk1OzZyNUC=
INA6 NHG0R5dHfW6ldHnvckBCe3OjeR?= M4PnVlIxKG6P NVGwXnd6QCCq M3\vdHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MknONVk1OzZyNUC=
OPM2 M4XXe2Z2dmO2aX;uJGF{e2G7 M{CwNFIxKG6P MWm4JIg> M4DjbXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 Ml7kNVk1OzZyNUC=
RPMI 8226 NUHi[WxITnWwY4Tpc44hSXO|YYm= MkLQNlAhdk1? MWm4JIg> MUnJcoR2[2W|IFTORUB{gW62aHXzbZM> MYCxPVQ{PjB3MB?=
BaF/3 M3G5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2raclExOCCwTR?= M2X6OFQ5KGh? M4ixZWlEPTB;Nj6yJI5O M3zufVIxOzB3Nkmy
BaF/3-p210 NWrlcGk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPqNVAxKG6P MYi0PEBp NULEUodmUUN3ME20Mlchdk1? MormNlA{ODV4OUK=
TCC-S Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxNFAhdk1? M3XySVQ5KGh? MVvJR|UxRTJwODDuUS=> MkjGNlA{ODV4OUK=
BaF/3 MmniSpVv[3Srb36gRZN{[Xl? MVO2JI5O NFjYSm01QCCq NXnWV2FVUW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 MnfiNlA{ODV4OUK=
BaF/3-p210 NH3Nd4VHfW6ldHnvckBCe3OjeR?= NGOzPW03KG6P NEjhc5E1QCCq MUDJcoR2[2W|IHGgd4xq\2i2IFexJINmdGxvY4njcIUh[XK{ZYP0 MVKyNFMxPTZ7Mh?=
BaF/3-p210 NGDne25HfW6ldHnvckBCe3OjeR?= NIGwc243KG6P NHm4U4wzPCCq NX;uTJZbWmWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGGwZDD0bIUh[WO2aY\peJkhd2ZiUnK= M3fJOFIxOzB3Nkmy
Raji M1;Oe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvnd4oyKM7:TR?= MlHJNlQhcA>? MX7S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MoTONlEyPzB7OEi=
LCL-1 NYrzNnNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LKXlEh|ryP M2q1W|I1KGh? MoPlVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M4TTeVIyOTdyOUi4
LCL-2 NUPI[5d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoruNUDPxE1? NVLRV4xuOjRiaB?= NUP6OYpbWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NWPlT48zOjFzN{C5PFg>
BJAB M1L0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljYNUDPxE1? NX3jfFV1OjRiaB?= MVTS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MWSyNVE4ODl6OB?=
SNT-13 NIPQS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf2cHdUOSEQvF2= MWOyOEBp NUTy[Fk5WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M3HKSFIyOTdyOUi4
SNT-16 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW1dXcyKM7:TR?= M3nJeVI1KGh? NXy3XXJFWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MnPHNlEyPzB7OEi=
Jurkat NIjaZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjYUHNMOSEQvF2= NUH6WXo6OjRiaB?= NV\CO5VRWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NVO0dJVMOjFzN{C5PFg>
KAI-3 MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:xJO69VQ>? NYfFXlhtOjRiaB?= MX3S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MlrBNlEyPzB7OEi=
SNK-6 NG\xbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHINUDPxE1? NEH0e28zPCCq MXPS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NGry[28zOTF5MEm4PC=>
KHYG-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKxJO69VQ>? Mo[1NlQhcA>? MXjS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M2nQeFIyOTdyOUi4
SNT-16 MnjXRZBweHSxc3nzJGF{e2G7 MWSxJO69VQ>? NVz1cFdwPiCq MYPJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NV65THlXOjFzN{C5PFg>
Jurkat M{DXTmFxd3C2b4Ppd{BCe3OjeR?= NWHiUWdKOSEQvF2= NI\RfpI3KGh? MlXTTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MnHaNlEyPzB7OEi=
KAI-3 NHjHNlBCeG:ydH;zbZMhSXO|YYm= MUixJO69VQ>? Mmm0OkBp Mnn5TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MYmyNVE4ODl6OB?=
KHYG-1 NUjCcFdjSXCxcITvd4l{KEG|c3H5 NHvCV5AyKM7:TR?= M{HCclYhcA>? NESwcoRKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NFTDVVczOTF5MEm4PC=>
SNT-13 M{T5ZWFvfGm4aYLhcEBCe3OjeR?= MmXKNUDPxE1? M4HTOVI1KGh? MUnJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> MXSyNVE4ODl6OB?=
SNT-16 MVvBcpRqfmm{YXygRZN{[Xl? MYCxJO69VQ>? NXPJcXllOjRiaB?= NIC1fHdKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NHPvTWMzOTF5MEm4PC=>
KAI-3 M2\iWWFvfGm4aYLhcEBCe3OjeR?= MXixJO69VQ>? NF:5XYgzPCCq NEXScJlKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NYP2N25ZOjFzN{C5PFg>
SNK-6 NEjZfWNCdnSrdnnyZYwhSXO|YYm= NF32fGcyKM7:TR?= NUKz[GVPOjRiaB?= NF64dIdKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MVOyNVE4ODl6OB?=
RAW 264.7 M2rLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSxNFAhdk1? Mlj3OFghcA>? NWrQOYdSWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NHjGSlUzOjR{N{G1OC=>
A375 M1f4W2Fxd3C2b4Ppd{BCe3OjeR?= MXyxNEBvVQ>? MWmyOEBp NH3Fb2NKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MXqyN|A4QTB6Mx?=
BLM Ml3qRZBweHSxc3nzJGF{e2G7 NH\iSJUyOCCwTR?= NXLxSHlmOjRiaB?= NG\MdIpKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M1rVNlI{ODd7MEiz
A375 M322VmF2fG:yaHHnfUBCe3OjeR?= MknmNVAhdk1? NGO5NoYyOiCq M4nHUmlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz M4f5TVI{ODd7MEiz
BLM NFWzTIhCfXSxcHjh[5khSXO|YYm= M3;5eVExKG6P NWO5NHQ5OTJiaB?= MmfqTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= NXXjb|lvOjNyN{mwPFM>
H1299 M2XGVmFxd3C2b4Ppd{BCe3OjeR?= MX24NEBvVQ>? NHvsZ|QzPCCq NGHJ[|ZFVVOR M{TRV3NmdnOrdHn6[ZMhVlOFTFOgZ4VtdHNidH:gUXNENWSncnn2[YQhcUN7LXnu[JVk\WRiYYDvdJRwe2m| M2npSlI2OzJ|Nkmz
Hut-78 NXjBSGRUTnWwY4Tpc44hSXO|YYm= NIXoZoUyODBibl2= MV:yOEBp MXPEUXNQ NI\XUolFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFyIHX4dJJme3Orb36= NHS1UXkzPTZ6MUOzOS=>
H9 NYiw[WhpTnWwY4Tpc44hSXO|YYm= MmrZNVAxKG6P NHmyW5IzPCCq MlzWSG1UVw>? NWLYbIQ{TG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;u MmLvNlU3QDF|M{W=
HH NVSzNWpmTnWwY4Tpc44hSXO|YYm= MnnwNVAxKG6P NHzZXpczPCCq NIfUVXRFVVOR NYHJVYoy\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u NEi4[GMzPTZ6MUOzOS=>
Hut-78 MYHNbYdz[XSrb36gRZN{[Xl? NYLI[ZpxOTByIH7N NFHEW3UzPCCq M{D5OWROW09? MnHHVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlyJR?= MYWyOVY5OTN|NR?=
HH MnfIUYloemG2aX;uJGF{e2G7 MVWxNFAhdk1? NH;J[4szPCCq MYLEUXNQ NWi2[m9nWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=> M3m3NlI2PjhzM{O1
U937 M4rlfWZ2dmO2aX;uJGF{e2G7 MUCxNFAhdk1? MXK2JIg> NYrmSYpCUW6mdXPld{BKVC16IHX4dJJme3Orb36gbY4hVFCVLYP0bY12dGG2ZXSgWVk{PyCvYXPyc5Bp[Wencx?= NI\T[XAzPTd7MUS3Oy=>
human PBMC MlHySpVv[3Srb36gRZN{[Xl? M3ewSFExOCCwTR?= NVHCe2JzOjRiaB?= MUXJcoR2[2W|IFnMMVghemWuZXHz[S=> MmTzNlU4QTF2N{e=
ES6 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K4UmlEPTB;MD6wNFIyKG6P M{DRRXNCVkeHUh?=
SK-UT-1 NYLNTnExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XwOWlEPTB;MD6xOlMhdk1? MYXTRW5ITVJ?
SH-4 NIi4TmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW0TWM2OD1yLkG3N{BvVQ>? NH3kOpZUSU6JRWK=
TE-9 M33oPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnqTnhFUUN3ME2wMlE5OiCwTR?= MV3TRW5ITVJ?
A253 NH:yVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jSZWlEPTB;MD6yNFghdk1? M3;xb3NCVkeHUh?=
no-10 M2nmRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMkGgcm0> MljBV2FPT0WU
MMAC-SF NXuzb5V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4OwNmlEPTB;MD6yNVYhdk1? NH2wcXFUSU6JRWK=
A101D NH7uSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fTVWlEPTB;MD6yNlUhdk1? MVnTRW5ITVJ?
NTERA-S-cl-D1 M{\JSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TkVWlEPTB;MD6yOFMhdk1? NFT3WVVUSU6JRWK=
8-MG-BA NFnldotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf2[HpKSzVyPUCuNlUhdk1? MUPTRW5ITVJ?
KNS-42 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLQcXRKSzVyPUCuNlU5KG6P MoK5V2FPT0WU
LXF-289 NV\adlRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvUTWM2OD1yLkK2PUBvVQ>? M1W3O3NCVkeHUh?=
OVCAR-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfFXW9KSzVyPUCuNlg6KG6P MYLTRW5ITVJ?
LOUCY NVHPW4JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoqwTWM2OD1yLkK5N{BvVQ>? MXXTRW5ITVJ?
BB65-RCC M2P3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fqWGlEPTB;MD6zNFQhdk1? NULTNotqW0GQR1XS
D-542MG NWDjZlVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwM{K5JI5O MUjTRW5ITVJ?
ONS-76 MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrVTWM2OD1yLkOzJI5O NX;KeXlsW0GQR1XS
BB30-HNC MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PVXWlEPTB;MD6zN|Uhdk1? NUP2S|NGW0GQR1XS
KS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTOe4pKSzVyPUCuN|Qhdk1? Mmj3V2FPT0WU
A388 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPOXWY4UUN3ME2wMlM2PiCwTR?= NIH1OmFUSU6JRWK=
ES8 M3rYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH74XI9KSzVyPUCuOEBvVQ>? NEfMVZVUSU6JRWK=
MZ2-MEL MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e0b2lEPTB;MD60NFchdk1? MVPTRW5ITVJ?
HCC2998 NXjtSo5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwNEGyJI5O M4TDPXNCVkeHUh?=
D-247MG MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\PXmlEPTB;MD60NVMhdk1? M3u5WXNCVkeHUh?=
ACN NGm2WIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwNEG3JI5O NXq3RnJnW0GQR1XS
LB2518-MEL NGHtTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH4XmdmUUN3ME2wMlQzPSCwTR?= MlyyV2FPT0WU
ES1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDBeWdKSzVyPUCuOFMhdk1? M{nSSXNCVkeHUh?=
HCE-T NUTXSlg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnizTWM2OD1yLkSzPUBvVQ>? M3Ty[nNCVkeHUh?=
OS-RC-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHxTWM2OD1yLkS0JI5O M4DPR3NCVkeHUh?=
MFH-ino NF7COoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPYTWM2OD1yLkS0N{BvVQ>? NVe3SYxFW0GQR1XS
OCUB-M NHjyUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[3ZmlJUUN3ME2wMlQ1PyCwTR?= MVTTRW5ITVJ?
CP66-MEL NHriVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwNEezJI5O M{[3RXNCVkeHUh?=
LB771-HNC NWW0TlJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLTWoc3UUN3ME2wMlQ4PCCwTR?= MXLTRW5ITVJ?
DSH1 NF7EbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwNEigcm0> NXrSUGJUW0GQR1XS
HUTU-80 NEOyXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwNUOzJI5O MUfTRW5ITVJ?
CESS MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwNUO4JI5O NUjWOWFnW0GQR1XS
NCI-H747 M4\4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrCNYFvUUN3ME2wMlU{QSCwTR?= NYnPUVQ3W0GQR1XS
HT-144 M{HOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwNUe2JI5O MoW1V2FPT0WU
COLO-829 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrsTlRKSzVyPUCuOlE1KG6P M2r6cnNCVkeHUh?=
A4-Fuk NVz1NoIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwNkKzJI5O M1zKdHNCVkeHUh?=
GI-ME-N MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fWVmlEPTB;MD62N|Qhdk1? NWD4c2dvW0GQR1XS
LB831-BLC NYPLUpcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17ERWlEPTB;MD62OFEhdk1? NVrEb3A4W0GQR1XS
HOP-62 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fOOWlEPTB;MD62OFchdk1? NYHtS2JZW0GQR1XS
BB49-HNC NFTEeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfMTWM2OD1yLk[1NkBvVQ>? NHLvfGhUSU6JRWK=
D-336MG M2XvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwNkW3JI5O M2rvXnNCVkeHUh?=
TK10 NIjz[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvydolKSzVyPUCuOlc6KG6P M4rub3NCVkeHUh?=
Ramos-2G6-4C10 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwNkmzJI5O M2DaOXNCVkeHUh?=
LB373-MEL-D NX;MUoNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwNzDuUS=> M3v0O3NCVkeHUh?=
SF126 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT2TWM2OD1yLkewNUBvVQ>? MULTRW5ITVJ?
UACC-257 NFnLcmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;QTWM2OD1yLkexJI5O MUjTRW5ITVJ?
KINGS-1 M4PkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\pUFJKSzVyPUCuO|IzKG6P MVjTRW5ITVJ?
LS-513 M3n0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfDW2NMUUN3ME2wMlc{QSCwTR?= NHTCbI5USU6JRWK=
GI-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj1TZRHUUN3ME2wMlc3PCCwTR?= MUDTRW5ITVJ?
ES7 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfHTWM2OD1yLke2OkBvVQ>? M{\HbHNCVkeHUh?=
LB2241-RCC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f0VGlEPTB;MD64NFQhdk1? NEP4c|hUSU6JRWK=
D-263MG NXyyOGJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj2OYNKSzVyPUCuPFA4KG6P NYSyUWhWW0GQR1XS
SW684 Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHrTWM2OD1yLkiyNUBvVQ>? NFfrbmxUSU6JRWK=
ML-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwOEKxJI5O NYS0RXF7W0GQR1XS
SK-LMS-1 NFHqS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwOEW0JI5O NG\DV5dUSU6JRWK=
TE-5 NFX3Xo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwOE[1JI5O M3q2SXNCVkeHUh?=
QIMR-WIL NHHWO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TIZ2lEPTB;MD64PFkhdk1? MlntV2FPT0WU
NCI-H1355 NVHPZmh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOwTWM2OD1yLki5OUBvVQ>? M1PlV3NCVkeHUh?=
SNB75 NXPT[It4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP3ZnVKSzVyPUCuPVEzKG6P NHr5TGdUSU6JRWK=
RXF393 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonETWM2OD1yLkmxOEBvVQ>? MoXyV2FPT0WU
IST-MEL1 NW\XXY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qwVGlEPTB;MD65NVchdk1? MW\TRW5ITVJ?
SF268 M2OzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrVeo9ZUUN3ME2wMlkzOyCwTR?= Mm\NV2FPT0WU
KALS-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjKTWM2OD1yLkmyOUBvVQ>? NULRUFMxW0GQR1XS
HC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rIeGlEPTB;MD65O|Uhdk1? NGL5Z5VUSU6JRWK=
SW872 NUnjVGZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwOUm2JI5O NXK0bWg3W0GQR1XS
PSN1 NGL2SldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zuOmlEPTB;MT6wNUBvVQ>? NWn0NIJxW0GQR1XS
TE-1 MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TESWlEPTB;MT6wN{BvVQ>? MVXTRW5ITVJ?
TE-10 M1LHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTlRYp5UUN3ME2xMlA{KG6P NVPLeJNlW0GQR1XS
RKO NGDWbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnYTWM2OD1zLkC2JI5O NH3yPJlUSU6JRWK=
LC-2-ad NIn6TGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDYTm1KSzVyPUGuNFghdk1? M4XpOXNCVkeHUh?=
SK-MM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwMEmgcm0> NWrUfYdDW0GQR1XS
VA-ES-BJ NYfqeVNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwMEmgcm0> M3z2UXNCVkeHUh?=
MZ7-mel NGW3O|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLKTWM2OD1zLkC5JI5O NWfCOGw{W0GQR1XS
D-392MG NWLrUmFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXZdpF5UUN3ME2xMlEhdk1? M4DQfXNCVkeHUh?=
CCRF-CEM M3zucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\HOXplUUN3ME2xMlE{KG6P NFHKOlhUSU6JRWK=
EM-2 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnETYpKSzVyPUGuNVYhdk1? NYrScmI1W0GQR1XS
HAL-01 NIXpU3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTnWGZ[UUN3ME2xMlE5KG6P MVfTRW5ITVJ?
TE-8 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PWUmlEPTB;MT6xPUBvVQ>? MVXTRW5ITVJ?
NCI-H1882 M2foeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37Nb2lEPTB;MT6yJI5O NX7kRZRsW0GQR1XS
Daudi M2fEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i2bWlEPTB;MT6yNkBvVQ>? MVrTRW5ITVJ?
BL-41 NGjtUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW0VItKSzVyPUGuNlUhdk1? MWrTRW5ITVJ?
SR NYPSSFFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwMkWgcm0> M1PpVnNCVkeHUh?=
KM12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC4TWM2OD1zLkK3JI5O M{fIWHNCVkeHUh?=
K5 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\FTWM2OD1zLkK4JI5O M{fVOXNCVkeHUh?=
A3-KAW Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvzc2dJUUN3ME2xMlI5KG6P M{XrW3NCVkeHUh?=
CMK MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j5emlEPTB;MT6yPUBvVQ>? NHzId3lUSU6JRWK=
Calu-6 M17vcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe1fnJKSzVyPUGuNlkhdk1? MVHTRW5ITVJ?
IST-SL2 NUCzcJZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WzRWlEPTB;MT6zNUBvVQ>? M3HtbHNCVkeHUh?=
OPM-2 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rqSWlEPTB;MT6zN{BvVQ>? NYjPblVxW0GQR1XS
DU-4475 NYWwRpB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFwM{[gcm0> NILUTXVUSU6JRWK=
ECC12 MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LEdWlEPTB;MT6zO{BvVQ>? NHPxXJJUSU6JRWK=
L-540 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq2RY5MUUN3ME2xMlM4KG6P NYPVdXdDW0GQR1XS
CAS-1 NH:yd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L2W2lEPTB;MT6zO{BvVQ>? M2PKSnNCVkeHUh?=
PF-382 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHUVZU6UUN3ME2xMlQ4KG6P NFHtWWxUSU6JRWK=
LS-411N MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\qSlZkUUN3ME2xMlU{KG6P M{[xfHNCVkeHUh?=
NCI-H69 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS4TWM2OD1zLkW0JI5O NY\0NVN4W0GQR1XS
NB12 NVvHPXFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwNU[gcm0> NFfJ[WlUSU6JRWK=
HEL NXnzXoVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwNkGgcm0> NV;YWmdQW0GQR1XS
GCIY NIjxd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED0e|JKSzVyPUGuOlIhdk1? MV\TRW5ITVJ?
EHEB NHzhOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\RSXRtUUN3ME2xMlY4KG6P MnKzV2FPT0WU
TGBC1TKB MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwN{Ggcm0> MX\TRW5ITVJ?
KURAMOCHI Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrPTWM2OD1zLkeyJI5O NGTJeohUSU6JRWK=
U-266 NHOw[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jnU2lEPTB;MT63OkBvVQ>? NU\SOmFqW0GQR1XS
LC4-1 M1uyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\acmdKSzVyPUGuO|khdk1? NHvyO4ZUSU6JRWK=
NCI-H2126 M4jJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nDXWlEPTB;MT64JI5O MYnTRW5ITVJ?
NCI-H1092 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrVdFJKSzVyPUGuPEBvVQ>? NXT0flBOW0GQR1XS
GB-1 NW\iPYR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILaN|dKSzVyPUGuPFEhdk1? MXnTRW5ITVJ?
MV-4-11 M2HkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTHVHBTUUN3ME2xMlgzKG6P NU\3THBLW0GQR1XS
Becker M4PZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLF[FRbUUN3ME2xMlg{KG6P NIXFeFZUSU6JRWK=
MPP-89 M4DrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwOEmgcm0> NF7H[HRUSU6JRWK=
BE-13 NH\OZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLETWM2OD1zLkmzJI5O NF7uWlNUSU6JRWK=
697 NWnqSpBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO3enprUUN3ME2xMlk6KG6P MXXTRW5ITVJ?
NKM-1 NUH4dm16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjmXodKSzVyPUKgcm0> M2nPSnNCVkeHUh?=
NB13 NYHHOlFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzyTWM2OD1{IH7N MmTNV2FPT0WU
LS-123 MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\pWZpKSzVyPUKuNFIhdk1? M{XEbXNCVkeHUh?=
NB17 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV34U|RYUUN3ME2yMlA1KG6P MXHTRW5ITVJ?
LAN-6 NHLHS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJwMEWgcm0> M{GzW3NCVkeHUh?=
EW-24 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPnXXFJUUN3ME2yMlA5KG6P MVjTRW5ITVJ?
NOS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLkN4YyUUN3ME2yMlEyKG6P MUnTRW5ITVJ?
BL-70 NEfnTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Tjb2lEPTB;Mj6xNkBvVQ>? NEf3bpZUSU6JRWK=
GT3TKB MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD6TWM2OD1{LkGyJI5O MXrTRW5ITVJ?
HH M2\aW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTNVmpMUUN3ME2yMlE{KG6P M2HpdnNCVkeHUh?=
KE-37 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\sTWM2OD1{LkGzJI5O NF7PdYdUSU6JRWK=
MOLT-4 NYi4RlRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjUVlE4UUN3ME2yMlE{KG6P MWfTRW5ITVJ?
EKVX M1HKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfRbY1XUUN3ME2yMlE1KG6P NXzuTnJ5W0GQR1XS
KGN MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvC[XBGUUN3ME2yMlE2KG6P MWPTRW5ITVJ?
ES4 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\oUYhKSzVyPUKuNVYhdk1? NYi0b3ZiW0GQR1XS
SJSA-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrGTWM2OD1{LkKxJI5O MYXTRW5ITVJ?
KMOE-2 NFfpZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvxVXFKSzVyPUKuNlMhdk1? M{jjSXNCVkeHUh?=
NB5 M1HFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDENYQ5UUN3ME2yMlI4KG6P MVvTRW5ITVJ?
BC-1 MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;Ue5hKSzVyPUKuN|Ehdk1? NV\uTI9SW0GQR1XS
NB10 NWXye2c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3HTWM2OD1{LkOyJI5O MkHJV2FPT0WU
RPMI-8226 NUDQUWZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJwM{Wgcm0> MXzTRW5ITVJ?
SCC-3 NIPJeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH4bHNwUUN3ME2yMlM4KG6P M1L4e3NCVkeHUh?=
ARH-77 MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHRVllKSzVyPUKuN|ghdk1? NV\ERXVpW0GQR1XS
NCI-H748 NWrWd4p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX4TWM2OD1{LkO5JI5O MlLqV2FPT0WU
KU812 NHrKVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\yb3U3UUN3ME2yMlQzKG6P M3fmPHNCVkeHUh?=
NCI-H64 NXjyVFVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPETWM2OD1{LkS0JI5O NVvOOJVQW0GQR1XS
NB69 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPENWRKSzVyPUKuOFYhdk1? MYjTRW5ITVJ?
KNS-81-FD MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi1V2lKSzVyPUKuOFghdk1? M{XlenNCVkeHUh?=
LB1047-RCC NXLGfVdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\TfmlEPTB;Mj61O{BvVQ>? NEPzb2JUSU6JRWK=
EB-3 NFrs[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LUV2lEPTB;Mj62OkBvVQ>? MlLTV2FPT0WU
Mo-T NUPKSWNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Xh[mlEPTB;Mj63OEBvVQ>? NY\5RXozW0GQR1XS
EW-16 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PSOGlEPTB;Mj63OUBvVQ>? NVO0Vlk1W0GQR1XS
CTV-1 M4LiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJwODDuUS=> M4nmVHNCVkeHUh?=
ETK-1 M2fjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHSflZIUUN3ME2yMlg1KG6P NWTpdXVPW0GQR1XS
C2BBe1 NH;POVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\aRZJ2UUN3ME2yMlg6KG6P NITPd25USU6JRWK=
MOLT-16 NEXFS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m1UmlEPTB;Mj64PUBvVQ>? MnjyV2FPT0WU
SW954 MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDOTWM2OD1{Lkmgcm0> MWDTRW5ITVJ?
HT NIDrRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfrUmsyUUN3ME2zMlAzKG6P NX\0RottW0GQR1XS
KARPAS-299 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNwME[gcm0> MnnzV2FPT0WU
MONO-MAC-6 NX\hZ4R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLve41uUUN3ME2zMlEhdk1? MXHTRW5ITVJ?
CGTH-W-1 MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTNwMTDuUS=> NU\iNnA1W0GQR1XS
SK-PN-DW NELsO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEiyUGRKSzVyPUOuNVQhdk1? MWLTRW5ITVJ?
CW-2 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XEN2lEPTB;Mz6yNUBvVQ>? NYj4VYRqW0GQR1XS
SK-N-DZ NGnv[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnRW2s6UUN3ME2zMlI3KG6P NX\BWnlXW0GQR1XS
NEC8 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvoN4hKSzVyPUOuN|Uhdk1? NHTxcHRUSU6JRWK=
LB996-RCC NX\ubZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HHS2lEPTB;Mz60JI5O NUnB[nY2W0GQR1XS
DB MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLZTWM2OD1|LkSxJI5O NIjnb3hUSU6JRWK=
TE-15 MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPLbWtoUUN3ME2zMlQ{KG6P MWXTRW5ITVJ?
COR-L88 M4TkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M330XGlEPTB;Mz60O{BvVQ>? NULvcoFrW0GQR1XS
LAMA-84 M2nC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV32R4I5UUN3ME2zMlQ6KG6P NXix[GVlW0GQR1XS
MEG-01 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Ve2VKSzVyPUOuOFkhdk1? MkjGV2FPT0WU
LOXIMVI MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTNwNTDuUS=> MoXGV2FPT0WU
RPMI-8402 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrRTWM2OD1|LkWgcm0> M2HOdXNCVkeHUh?=
KARPAS-45 NILMUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwNUSgcm0> MnThV2FPT0WU
HCC1187 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7kTWM2OD1|LkW0JI5O MWHTRW5ITVJ?
MZ1-PC NVHwNnBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTNwNUSgcm0> MnK3V2FPT0WU
no-11 NHzyTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH4XWdKSzVyPUOuOVUhdk1? NYrHfJByW0GQR1XS
EVSA-T MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXYTWM2OD1|Lk[gcm0> NWe1eoNvW0GQR1XS
DJM-1 NFvmcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\2TWM2OD1|Lk[zJI5O M{nDfHNCVkeHUh?=
COLO-684 MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf3OFhKSzVyPUOuOlYhdk1? Mn;BV2FPT0WU
NMC-G1 NHP2TmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M171b2lEPTB;Mz62PEBvVQ>? NV;HdmJPW0GQR1XS
LC-1F MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNwN{Sgcm0> NVnjeIJVW0GQR1XS
RL95-2 Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PaXGlEPTB;Mz63PUBvVQ>? MlnxV2FPT0WU
COLO-320-HSR M37pSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonFTWM2OD1|LkmyJI5O NUHoblF{W0GQR1XS
RCC10RGB NIHYd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPYfHRKSzVyPUOuPVMhdk1? MmHnV2FPT0WU
HD-MY-Z MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP6TWM2OD1|LkmzJI5O M{XRbHNCVkeHUh?=
NCI-H2141 NXHDdIF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS3TWM2OD12LkC1JI5O M{LZfXNCVkeHUh?=
K-562 NUPibZY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTRwMUKgcm0> MYfTRW5ITVJ?
NCI-H1648 NUTnR5c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;WfWlEPTB;ND6xN{BvVQ>? NHS5cIdUSU6JRWK=
OMC-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT0TWM2OD12LkG4JI5O M1S2PXNCVkeHUh?=
LB647-SCLC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3kTWM2OD12LkKyJI5O MnHIV2FPT0WU
TE-12 M2nwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfpWVRKSzVyPUSuNlUhdk1? M4jZbHNCVkeHUh?=
NOMO-1 Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL3TWM2OD12LkOzJI5O NHK1OFBUSU6JRWK=
Raji M2LHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLQeJJKSzVyPUSuOFYhdk1? MmLiV2FPT0WU
NALM-6 MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrSO3VrUUN3ME20MlQ6KG6P MWDTRW5ITVJ?
HL-60 NUjWTphRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXOyWIZLUUN3ME20MlY4KG6P MXjTRW5ITVJ?
IST-SL1 M3PVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD0bZpGUUN3ME20MlY5KG6P MVnTRW5ITVJ?
MHH-PREB-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTRwOE[gcm0> NF\oWWdUSU6JRWK=
MHH-NB-11 NY\4VHB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXJTWM2OD12LkmxJI5O NFjjWVFUSU6JRWK=
JiyoyeP-2003 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLrTWM2OD13IH7N NVzYbWJWW0GQR1XS
SBC-1 NIPXRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO2VpZKSzVyPUWuNFEhdk1? NH\lcHBUSU6JRWK=
CHP-126 NH\YNHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfaTWM2OD13LkC2JI5O MkPjV2FPT0WU
LU-139 MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKwXmVKSzVyPUWuNVMhdk1? NXLOblQxW0GQR1XS
NCI-SNU-5 Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\aOmE2UUN3ME21MlE4KG6P NYrEVHV1W0GQR1XS
SW962 NIXQcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T1VGlEPTB;NT6yNUBvVQ>? MlTXV2FPT0WU
EW-1 M1T5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;PeWZJUUN3ME21MlMyKG6P MX3TRW5ITVJ?
NCI-H1417 NWfwPXc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33yWmlEPTB;NT61NUBvVQ>? MVLTRW5ITVJ?
LU-65 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnETWM2OD13Lki0JI5O MkfjV2FPT0WU
D-502MG NYfzPYV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITXdm1KSzVyPU[uN|chdk1? MV\TRW5ITVJ?
BC-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPK[phKSzVyPU[uOlEhdk1? NXTNSJJ[W0GQR1XS
GDM-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvhOGpXUUN3ME22Mlc4KG6P NVvWTmdIW0GQR1XS
NCI-H2196 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHlTWM2OD14Lkigcm0> NVPtOoJ[W0GQR1XS
NB1 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjI[XZbUUN3ME22Mlg5KG6P MVLTRW5ITVJ?
NCI-H345 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTzTWM2OD15LkKgcm0> M2C3dXNCVkeHUh?=
SU-DHL-1 NFX5em9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrpcHVKSzVyPUeuNlQhdk1? MWnTRW5ITVJ?
JVM-2 NYmxXVdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\vN2lEPTB;Nz6yPEBvVQ>? NYfnbZJiW0GQR1XS
LU-134-A M3j0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrmcWpLUUN3ME23MlM6KG6P M3PpWXNCVkeHUh?=
NCI-H1694 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\k[3BKSzVyPUeuOVghdk1? NYrSV2k2W0GQR1XS
NCI-SNU-16 NHv2UpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\pTWM2OD15Lk[1JI5O NIjRdYpUSU6JRWK=
L-363 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTdwNzDuUS=> MVfTRW5ITVJ?
KG-1 M{nOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTdwOUSgcm0> NVT6SopIW0GQR1XS
MN-60 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:1fJZKSzVyPUiuNVQhdk1? MYDTRW5ITVJ?
NB6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjITWM2OD16LkS4JI5O NIj4U|FUSU6JRWK=
MLMA MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\XXoxKSzVyPUiuPFUhdk1? MnXkV2FPT0WU
ATN-1 MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fITWlEPTB;OD64PUBvVQ>? MkDDV2FPT0WU
SK-NEP-1 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTlwMEGgcm0> Mo\qV2FPT0WU
DMS-114 M1nxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLqXW5ZUUN3ME25MlYzKG6P NIm5OYVUSU6JRWK=
CTB-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Dn[GlEPTB;OT62O{BvVQ>? MXnTRW5ITVJ?
NCI-H2081 MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTCTWM2OD1zMD6wPUBvVQ>? MlPUV2FPT0WU
ES5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\yTWM2OD1zMD6zPEBvVQ>? M4HPdnNCVkeHUh?=
HCC1599 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;J[VN4UUN3ME2xNU46OSCwTR?= MWjTRW5ITVJ?
NCI-H23 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y0cWlEPTB;MUKuNVIhdk1? MlLWV2FPT0WU
NCI-H1581 NXj2b4NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jGfmlEPTB;MUKuNlghdk1? MmfSV2FPT0WU
JVM-3 NW\kfIhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe1SHRKSzVyPUGyMlk6KG6P NED3[YdUSU6JRWK=
NCI-SNU-1 M4nWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\i[GlEPTB;MUOuNVkhdk1? NHzzR|BUSU6JRWK=
NB7 MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W1XGlEPTB;MUWuPVIhdk1? MYLTRW5ITVJ?
JAR MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF4LkGzJI5O M1PYRnNCVkeHUh?=
TGW M{LoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;JTWM2OD1zNj60PEBvVQ>? M2DTbXNCVkeHUh?=
U-87-MG Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rCcWlEPTB;MU[uO|Yhdk1? MVjTRW5ITVJ?
NCI-H1436 NGHScI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL2TWM2OD1zNz6wNUBvVQ>? M2joWXNCVkeHUh?=
GOTO NETxZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r3SmlEPTB;MUeuNFYhdk1? NHzSSGRUSU6JRWK=
COLO-800 NHfiNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF5Lk[0JI5O NYSzSpREW0GQR1XS
MFM-223 Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF5LkmxJI5O NULteXF7W0GQR1XS
EW-18 MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ZTWM2OD1zNz65OkBvVQ>? M3TuTHNCVkeHUh?=
NB14 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDY[5lKUUN3ME2xO{46QCCwTR?= M{DPOnNCVkeHUh?=
EB2 NFTRXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF6LkC4JI5O NXzINXlJW0GQR1XS
EoL-1- NEfDOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jufmlEPTB;MUiuN|Ehdk1? NX\iNogxW0GQR1XS
NCCIT M3;mZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[wdFVXUUN3ME2xPE4{PiCwTR?= NFPYfotUSU6JRWK=
DG-75 M3\pd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfGVnUxUUN3ME2xPE43OSCwTR?= NHnLdGdUSU6JRWK=
HCC2218 NFTsdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF7LkWgcm0> M1\BUHNCVkeHUh?=
TE-6 M4KxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL1TWM2OD1{MD6wPEBvVQ>? NFz5OFRUSU6JRWK=
SF539 M2\jbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO0TWM2OD1{MD62O{BvVQ>? NGjVS3NUSU6JRWK=
NCI-H446 Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELreGlKSzVyPUKxMlE5KG6P M37DTXNCVkeHUh?=
IST-MES1 NFXPbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTUTWM2OD1{Mj63O{BvVQ>? NITwVJdUSU6JRWK=
NCI-H82 NEH3V4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLHTWM2OD1{Mz6wNkBvVQ>? MmHBV2FPT0WU
HCC2157 MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DROGlEPTB;MkOuNVMhdk1? M{PM[nNCVkeHUh?=
EW-12 MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NISxV|RKSzVyPUKzMlE4KG6P NHHNb4lUSU6JRWK=
SIMA MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJ|LkO4JI5O NIfGdVNUSU6JRWK=
DOHH-2 NWfBfGtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlznTWM2OD1{Mz60OUBvVQ>? M4qyT3NCVkeHUh?=
IM-9 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfBPW9QUUN3ME2yN{42PCCwTR?= MYjTRW5ITVJ?
EC-GI-10 MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD5TWM2OD1{ND6yN{BvVQ>? MVXTRW5ITVJ?
HDLM-2 NUnYdmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTNUmJrUUN3ME2yOE42PCCwTR?= Mo\ZV2FPT0WU
LS-1034 MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ3Lke1JI5O MXXTRW5ITVJ?
REH MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvjTWM2OD1{Nj60NUBvVQ>? Mn[xV2FPT0WU
LU-165 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u4SmlEPTB;Mk[uO|Ihdk1? MnjoV2FPT0WU
NH-12 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJ5Lk[3JI5O MWrTRW5ITVJ?
WSU-NHL MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDETWM2OD1{OD6zPUBvVQ>? MUnTRW5ITVJ?
ECC4 NH3SOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT1ZZdKSzVyPUK4Mlc6KG6P Mln2V2FPT0WU
OCI-AML2 NUj3PYtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF22TYJKSzVyPUK5MlY6KG6P NV24XlNzW0GQR1XS
EW-3 NVj4TVh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn0eGlKSzVyPUOwMlU6KG6P MVvTRW5ITVJ?
NCI-H526 NHXvOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;PTWM2OD1|Mj61OEBvVQ>? NV:5ToJ6W0GQR1XS
NCI-H719 NU\n[4l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;MTWM2OD1|ND6zNUBvVQ>? NVXTNotxW0GQR1XS
KARPAS-422 NGfncIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjFUolKSzVyPUO1MlA1KG6P MX\TRW5ITVJ?
SK-MEL-1 NIf3V29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zmZWlEPTB;M{WuNVchdk1? MlP0V2FPT0WU
ES3 NX\GdXRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\mTWM2OD1|NT6xPUBvVQ>? MYTTRW5ITVJ?
UACC-812 Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jwT2lEPTB;M{WuOFQhdk1? M1;yfnNCVkeHUh?=
C8166 NUHnc213T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrQeI1KSzVyPUO1Mlchdk1? NUPDWHo4W0GQR1XS
MDA-MB-134-VI NHrYUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnFT|hKSzVyPUO1Mlg4KG6P Mn\IV2FPT0WU
D-283MED MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7KT5d2UUN3ME2zO{44QSCwTR?= M3[0cnNCVkeHUh?=
SHP-77 Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHOTWM2OD1|OD6wN{BvVQ>? NULGVpc{W0GQR1XS
NCI-H2227 NGTYRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTRyLkS5JI5O NX7ubWhpW0GQR1XS
SKM-1 M2THdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfQWJdwUUN3ME20Nk43OyCwTR?= MYnTRW5ITVJ?
L-428 NVrPSXE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLzVoZ3UUN3ME20N{45PiCwTR?= NHHWOYlUSU6JRWK=
RPMI-6666 MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33j[GlEPTB;NEWuPFkhdk1? MmHPV2FPT0WU
NCI-H716 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLVTWM2OD12OD64NUBvVQ>? NFH0UnVUSU6JRWK=
DMS-79 NGnldWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vkVGlEPTB;NUCuO|Ehdk1? NWPsOolHW0GQR1XS
RS4-11 MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTBTWM2OD13MD64PEBvVQ>? MmLpV2FPT0WU
NCI-H720 NVKz[JlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PMcGlEPTB;NUGuNVEhdk1? M1G2S3NCVkeHUh?=
MC-CAR MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XwNGlEPTB;NUGuOVIhdk1? NFf1SHFUSU6JRWK=
TALL-1 NHO5R29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrWTWM2OD13Mz65NUBvVQ>? M2DJVXNCVkeHUh?=
NCI-N87 M1X5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;lTWM2OD13ND6xPEBvVQ>? Ml\nV2FPT0WU
P30-OHK MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTuTWM2OD13ND62NUBvVQ>? MW\TRW5ITVJ?
LP-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTZzLkK4JI5O NGXJPIxUSU6JRWK=
YT M1nqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jnZWlEPTB;NkGuPEBvVQ>? NFvJ[mpUSU6JRWK=
MRK-nu-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH1NpZIUUN3ME22NU45OiCwTR?= M2XKXnNCVkeHUh?=
BT-474 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4WyTGlEPTB;NkWgcm0> M2XrTHNCVkeHUh?=
NCI-H322M NWG4b2w4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKzTWM2OD14Nj6xNUBvVQ>? NH3rS|dUSU6JRWK=
NCI-H128 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom5TWM2OD15ND63O{BvVQ>? NWrBc4JlW0GQR1XS
KMS-12-PE NYfGfIhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTd4LkK0JI5O NFf4TYhUSU6JRWK=
KP-N-YS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnRTWRbUUN3ME23Ok44PCCwTR?= NHm2XJJUSU6JRWK=
ALL-PO MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LycWlEPTB;N{euOlYhdk1? MoO5V2FPT0WU
EW-13 Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTGS2htUUN3ME23O{44PiCwTR?= Ml62V2FPT0WU
EW-11 NF7RWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rBd2lEPTB;N{iuOVIhdk1? NVLJUlF7W0GQR1XS
SK-N-FI M4C5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRThyLkKgcm0> NIC5b4xUSU6JRWK=
CAL-148 M1rBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDmN3BKSzVyPUixMlg1KG6P M2LLNXNCVkeHUh?=
RL MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTh4LkC5JI5O MkHPV2FPT0WU
AM-38 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;3TWM2OD16OD6wPEBvVQ>? NGDDRWtUSU6JRWK=
RH-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jFOGlEPTB;OUmuPFUhdk1? NHm4dmNUSU6JRWK=
NCI-H1770 MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KweGlEPTB;MUCyMlQ6KG6P NXPMT5l6W0GQR1XS
SIG-M5 MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFyNT6wOkBvVQ>? MoDhV2FPT0WU
GR-ST M{HhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETFW5lKSzVyPUGxN{4{PCCwTR?= MWPTRW5ITVJ?
ST486 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H2eWlEPTB;MUG0MlA3KG6P NWrvO5hUW0GQR1XS
NCI-H1650 NH\FOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnOSFFoUUN3ME2xNVUvOjlibl2= MU\TRW5ITVJ?
MHH-CALL-2 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj6[3BKSzVyPUGxOU44KG6P M1jwcHNCVkeHUh?=
BV-173 NFLSWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjJd|hnUUN3ME2xNlIvPzFibl2= NU\Vd5FIW0GQR1XS
MC116 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF2OD64OUBvVQ>? NIjoc3JUSU6JRWK=
NCI-H524 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjkPXZpUUN3ME2xOVkvOSCwTR?= MmSzV2FPT0WU
SCLC-21H NXfR[2d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF3OT60NUBvVQ>? MUPTRW5ITVJ?
NCI-H1304 Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXPb4tKSzVyPUG2PU4zOSCwTR?= M4rIWXNCVkeHUh?=
NCI-H510A NHfMdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF6NT6zO{BvVQ>? MnjPV2FPT0WU
NCI-H209 M335ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF7Nj61NkBvVQ>? M1LYcXNCVkeHUh?=
KM-H2 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe0WoFKSzVyPUG5O{4xPSCwTR?= NIC2Z4NUSU6JRWK=
NCI-H1395 NYrxcXNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPC[|lTUUN3ME2yNVAvOTNibl2= NHPMblJUSU6JRWK=
NCI-H1155 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;XTWM2OD1{M{CuN|Ihdk1? NXv2TJVWW0GQR1XS
COR-L279 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ3Mj6xO{BvVQ>? MlvkV2FPT0WU
NCI-H1299 NGX6fXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\GNndoUUN3ME2yOlEvPzFibl2= MmnRV2FPT0WU
EW-22 M164NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJ4Mz63OUBvVQ>? NWj0cmd7W0GQR1XS
SK-MEL-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInBcm5KSzVyPUK4NU46KG6P MoHJV2FPT0WU
KASUMI-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJ6Mz6wOUBvVQ>? NFvNXmZUSU6JRWK=
NCI-H187 MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULxVVVKUUN3ME2yPFcvODhibl2= MYTTRW5ITVJ?
NCI-H2171 NEnTO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LiTGlEPTB;Mki4MlkzKG6P MnnpV2FPT0WU
LNCaP-Clone-FGC NWXuWGJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrkfZFtUUN3ME2yPVUvOjZibl2= M4G2T3NCVkeHUh?=
NCI-H1522 NF7OSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TSZ2lEPTB;M{C3MlA2KG6P NXfYRXVrW0GQR1XS
SCH NFrOWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TrcWlEPTB;M{KyMlIzKG6P NGPicFJUSU6JRWK=
THP-1 NVXtSI57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPGb3hnUUN3ME2zNlIvPiCwTR?= MXnTRW5ITVJ?
SNU-C1 NUfOV28{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknFTWM2OD1|NkKuNFkhdk1? NXzyWHpIW0GQR1XS
CA46 M13qTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPuOnVIUUN3ME2zO|MvPjNibl2= MX7TRW5ITVJ?
NCI-H1963 M3mxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;FfXRiUUN3ME2zPFYvOTlibl2= MlL3V2FPT0WU
DEL MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\TXmlEPTB;M{mxMlI4KG6P Mn;rV2FPT0WU
TUR NFn4TJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:zTWM2OD1|OU[uOlEhdk1? NWHIV25uW0GQR1XS
NCI-H226 M4nCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CwO2lEPTB;NECzMlI{KG6P NI\qVm1USU6JRWK=
COLO-668 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnoTnBKSzVyPUSwN{42PyCwTR?= MUfTRW5ITVJ?
CPC-N M1\NW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTRyMz63O{BvVQ>? Mlq5V2FPT0WU
NCI-H889 NHL5XpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR4MT65NkBvVQ>? NHjvb3hUSU6JRWK=
J-RT3-T3-5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fabWlEPTB;NUOyMlU4KG6P M1rHb3NCVkeHUh?=
MSTO-211H NY[3O5dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvzc5ZKSzVyPUW3OE4zPiCwTR?= NEXvRVVUSU6JRWK=
SCC-15 M1fOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHuc|ZKSzVyPU[2O{41PyCwTR?= MnT6V2FPT0WU
SUP-T1 NX7PUpdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Dyd2lEPTB;Nki2MlA1KG6P NHm4cFFUSU6JRWK=
DMS-153 M1rtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC3eINKSzVyPUe0Ok45OyCwTR?= MmfxV2FPT0WU
MS-1 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\Se3RKSzVyPUe1PU41OiCwTR?= NHTTW2lUSU6JRWK=
TC-YIK MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH3dm03UUN3ME23PFEvODFibl2= NH\wR5JUSU6JRWK=
RPMI-8866 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrmU2hiUUN3ME2xNFA3NjJ6IN88US=> MYTTRW5ITVJ?
KY821 NXrSbIhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfPVW9PUUN3ME2xNFM3NjB2IN88US=> Mkm2V2FPT0WU
P31-FUJ NGTiZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFzMUKuO|Uh|ryP NVzYS|c3W0GQR1XS
COLO-824 MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;qboVxUUN3ME2xNlYyNjd6IN88US=> NYDacINGW0GQR1XS
U-698-M M1rsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHFTWM2OD1{Mk[yMlE2KM7:TR?= NH;iPGdUSU6JRWK=
TE-441-T NWniOJg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\OdVVnUUN3ME2yOVIyNjdizszN M4rvSHNCVkeHUh?=
IMR-5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPJRo1KSzVyPUO0NFkvPjJizszN M33qZnNCVkeHUh?=
NCI-H1838 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnCTXJOUUN3ME20NVg3NjN{IN88US=> NEOzfWlUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID